The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The medicines regulator has flagged up a small increased risk of Guillain-Barré syndrome after RSV vaccination in adults over ...

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

The U.S. Food and Drug Administration has approved three vaccines for RSV — GSK's Arexvy, Moderna's mRESVIA and Pfizer's ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

A group of mothers in Victoria say they've experienced trouble accessing the jab for a highly infectious illness that infects ...

For pregnant women, the CDC and ACIP continue to recommend a single dose of RSV vaccine (ABRYSVO) between 32 and 36 weeks’ gestation.